Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

Marco Tartaglia, Ernest L. Mehler, Rosalie Goldberg et al. · Nature Genetics · 2001 · 1.7K citations

Life Sciences, Genetics, Molecular Genetics +11

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.5K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +7

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +11

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante et al. · The Lancet Oncology · 2012 · 542 citations · Full text

Medicine, Oncology, Pharmacology +17